GlassScriptPhysician profile
Timothy Alan Darnell
NPI 1467678979
$3,509.67
in general payments reported to CMS, 2019-2025
18 companies · $1,184 in 2025
The $1,184 reported for 2025 was more than what 81% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $112 · 2020: $207 · 2021: $357 · 2022: $165 · 2023: $506 · 2024: $977 · 2025: $1,184.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,575 · Education: $93.60.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,574.59 |
| Education | $93.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $1,291.32 | 2020-2025 | Dovato, Cabenuva, Apretude |
| Gilead Sciences, INC. | $660.59 | 2019-2025 | Biktarvy |
| Insmed, INC. | $274.36 | 2022-2025 | Arikayce |
| Merck Sharp & Dohme LLC | $247.14 | 2023-2025 | Zerbaxa, Dificid, Capvaxive |
| Abbvie INC. | $220.84 | 2021-2025 | Avycaz, Dalvance |
| Takeda Pharmaceuticals U.S.A., INC. | $185.36 | 2021-2025 | Hyqvia, Cuvitru |
| Shionogi INC | $128.80 | 2023-2025 | Fetroja |
| Astellas Pharma US INC | $101.73 | 2025 | Cresemba |
| Electromed, INC. | $82.22 | 2021-2024 | Smartvest |
| Janssen Products, LP | $69.99 | 2019 | |
| Allergan, INC. | $60.17 | 2019-2020 | |
| Paratek Pharmaceuticals, INC. | $56.35 | 2022-2025 | Nuzyra |
| Ferring Pharmaceuticals INC. | $40.33 | 2023-2024 | Rebyota |
| La Jolla Pharmaceutical Company | $21.26 | 2023 | Xerava |
| Aimmune Therapeutics, INC. | $20.09 | 2025 | Zenpep |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $19.46 | 2025 | |
| Janssen Biotech, INC. | $17.29 | 2023 | Symtuza |
| Dynavax Technologies Corporation | $12.37 | 2025 | Heplisav-B |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Darnell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.